Cargando…

Liquid Biopsy in Non-Small Cell Lung Cancer

Liquid biopsy analyses are already incorporated in the routine clinical practice in many hospitals and oncology departments worldwide, improving the selection of treatments and monitoring of lung cancer patients. Although they have not yet reached its full potential, liquid biopsy-based tests will s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molina-Vila, Miguel A., Mayo-de-las-Casas, Clara, Giménez-Capitán, Ana, Jordana-Ariza, Núria, Garzón, Mónica, Balada, Ariadna, Villatoro, Sergi, Teixidó, Cristina, García-Peláez, Beatriz, Aguado, Cristina, Catalán, María José, Campos, Raquel, Pérez-Rosado, Ana, Bertran-Alamillo, Jordi, Martínez-Bueno, Alejandro, Gil, María-de-los-Llanos, González-Cao, María, González, Xavier, Morales-Espinosa, Daniela, Viteri, Santiago, Karachaliou, Niki, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179978/ https://www.ncbi.nlm.nih.gov/pubmed/28066769 http://dx.doi.org/10.3389/fmed.2016.00069

Ejemplares similares

Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
por: Mayo de las Casas, Clara, et al.
Publicado: (2019)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
por: Villatoro, Sergio, et al.
Publicado: (2019)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Advances in immunotherapy for treatment of lung cancer
por: Bustamante Alvarez, Jean G., et al.
Publicado: (2015)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
por: Karachaliou, Niki, et al.
Publicado: (2018)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response
por: Gonzalez-Cao, Maria, et al.
Publicado: (2016)

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
por: Santarpia, Mariacarmela, et al.
Publicado: (2011)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
por: Malapelle, Umberto, et al.
Publicado: (2017)

Activation of viral defense signaling in cancer
por: Gonzalez-Cao, Maria, et al.
Publicado: (2018)

RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients
por: Aguado, Cristina, et al.
Publicado: (2020)

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Detecting ALK , ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
por: Giménez‐Capitán, Ana, et al.
Publicado: (2023)

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
por: Nilsson, R. Jonas A., et al.
Publicado: (2015)

TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma
por: Yue, Guofeng, et al.
Publicado: (2014)

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
por: Simonetti, Sara, et al.
Publicado: (2010)

Human endogenous retroviruses and cancer
por: Gonzalez-Cao, María, et al.
Publicado: (2016)

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer
por: Aguado, Cristina, et al.
Publicado: (2020)

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer
por: Pedraz-Valdunciel, Carlos, et al.
Publicado: (2022)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Addressing Health Disparities through Community Participation: A Scoping Review of Co-Creation in Public Health
por: Morales-Garzón, Sergio, et al.
Publicado: (2023)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges
por: Karachaliou, Niki, et al.
Publicado: (2018)

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018)

Rhomboids and regulation of receptor tyrosine kinase ligands shedding
por: Karachaliou, Niki, et al.
Publicado: (2018)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy
por: Rosell, Rafael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jrc5aa95tqtgta4ri5kn1li2ue